Next report date
Report period
Q1 2024
EPS estimate
−0.97CHF
Revenue estimate
202.53 MCHF
−12.493CHF
−640.29 MCHF
883.44 MCHF
50.09 M
About Emergent Biosolutions, Inc.
Sector
CEO
Joseph C. Papa
Headquarters
Gaithersburg
Website
Employees (FY)
1.6 K
Founded
1998
FIGI
BBG00LVD90Z2
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
Emergent Biosolutions (EBS) - signs of potential breakout 4-hourEmergent Biosolutions (EBS) - signs of potential breakout
Emergent Biosolutions (EBS):
EBS is a clinical-stage biotechnology company developing a novel vaccine for pneumonia. The company's stock has been undervalued for some time, but it is starting to show signs of a breakout. The stock is u
Possible Pneumonia Stocks - signs of potential breakoutPossible Pneumonia Stocks - signs of potential breakout
Emergent Biosolutions (EBS) :
EBS is a clinical-stage biotechnology company developing a novel vaccine for pneumonia. The company's stock has been undervalued for some time, but it is starting to show signs of a breakout . The stock i
OD's In America EBS has THE main stream Narcan that dominates the market. With increasing over doses though out America. Earnings could make this move like crazyyyyyyyy.
If it is not this earnings then it is next, this stock can pop 50-100% in one day. Its a scalp trade.
EBS a biotech company focused on vaccinesEBS is a small biotechnology company whose forte is the clean processing and manufacturing
facility that the FDA requires for certain bioprocessing to be certified for delivery of products
to end-user patients. It is not a research facility like the one in China that accidentally released
COVID
$EBS - Narcan over the counter nose spray & Earnings 2/27I usually stray away from bio/biotech b/c of how volatile it is, but $EBS seems to be established with a $800M+ market cap, strong historicals, 20 PE ratio, and seems to be getting close to bottom. They also have an exciting narcan nasal spray product that can be sold over the counter they are worki
EBS long 12.00-9.00$The price is approaching the strong level of $10.60, and there is already increased interest in this stock. This stock has been showing growth in December for many years, so it makes sense to consider buying in the $12.00-9.00 area, stop-loss at $8.5. The first target is $25, the second target is $3
Is EBS a buy as it hits a critical support level? EBS is currently hitting a critical support level around the 25 levels, which has been tested multiple times as key support and resistance level since 2009.
I am planning on buying at this current level, with a very high-profit target and a tight 5% stop loss below the support level. The ATH is ov
EBS: It's pretty bad when you underperform TNXPConsidering TNXP does... well... nothing, EBS underperforming TNXP is disappointing. Still holding and will continue to buy shares if SP falls back into the gray area at $25-$32. Monthly hammer + continuation off a high volume node + 2.618 fib should indicate a trend reversal.
EBS was never a "sque
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ER4 is 1.899 CHF — it has decreased by 13.52% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange EMERGENT BIOSOLUTI stocks are traded under the ticker ER4.
EMERGENT BIOSOLUTI is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
ER4 stock is 15.64% volatile and has beta coefficient of 2.26. Check out the list of the most volatile stocks — is EMERGENT BIOSOLUTI there?
ER4 earnings for the last quarter are −0.49 CHF per share, whereas the estimation was −0.20 CHF resulting in a −141.79% surprise. The estimated earnings for the next quarter are −0.16 CHF per share. See more details about EMERGENT BIOSOLUTI earnings.
EMERGENT BIOSOLUTI revenue for the last quarter amounts to 247.64 M CHF despite the estimated figure of 217.37 M CHF. In the next quarter revenue is expected to reach 247.03 M CHF.
Yes, you can track EMERGENT BIOSOLUTI financials in yearly and quarterly reports right on TradingView.
ER4 stock has fallen by 13.52% compared to the previous week, the month change is a 13.52% fall, over the last year EMERGENT BIOSOLUTI has showed a 83.16% decrease.
ER4 net income for the last quarter is −41.68 M CHF, while the quarter before that showed −241.14 M CHF of net income which accounts for 82.72% change. Track more EMERGENT BIOSOLUTI financial stats to get the full picture.
Today EMERGENT BIOSOLUTI has the market capitalization of 91.53 M, it has increased by 2.83% over the last week.
No, ER4 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ER4 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EMERGENT BIOSOLUTI stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 28, 2024, the company has 1.60 K employees. See our rating of the largest employees — is EMERGENT BIOSOLUTI on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EMERGENT BIOSOLUTI technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EMERGENT BIOSOLUTI stock shows the sell signal. See more of EMERGENT BIOSOLUTI technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on EMERGENT BIOSOLUTI future price: according to them, ER4 price has a max estimate of 4.39 CHF and a min estimate of 4.39 CHF. Read a more detailed EMERGENT BIOSOLUTI forecast: see what analysts think of EMERGENT BIOSOLUTI and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EMERGENT BIOSOLUTI EBITDA is −43.70 M CHF, and current EBITDA margin is −4.09%. See more stats in EMERGENT BIOSOLUTI financial statements.